Aldevron Breakthrough Blog: Corporate News

Forum Report: Aldevron's expansion could equate to $500 million for region

News report courtesy Forum Communication, written by Barry Amundson. Published August 29, 2019

Tax incentive supporters are putting the pressure on to show that programs being offered to businesses and developers are not only going to eventually provide impressive property tax payments but also provide positive ripple effects in the community.

Read More

Aldevron capacity, capability growth key to gene, cell and protein therapeutics research

0319-GEN-logoAldevron is "Driven by a Passion to Enable Science," as featured in the April Genetic Engineering & Biotechnology News. This article spans our new production facility in Fargo, North Dakota, and the expansion of our Freiburg, Germany, antibody facility, to our expanding CRISPR options, the publication discusses our ongoing push to help researchers in their work.

One particular highlight is the discussion of our new CRISPR options, including GMP level SpyFiTM Cas9 Nuclease and the availability of in-stock GMP level prepacked CRISPR nucleases.

Read More

Aldevron sponsors Emily Whitehead Foundation Believe Ball

Aldevron, a global provider of plasmid DNA and gene editing enzymes used to support novel cancer therapies, will be a Platinum sponsor of the 2017 Believe Ball organized by the Emily Whitehead Foundation. In its inaugural year, the Believe Ball will bring together T-Cell therapy patients and their families with the doctors, scientists, researchers, and others who helped develop this therapy.

Read More

Helping create future scientists

We never know where roads will lead us, though one roadmap we’re proud of providing is one of internships, helping develop scientific talent in our growing biotechnology industry.

It is great to be able to provide the opportunity and watch students getting involved in the industry while being able to apply what they are learning at college to the work going on in the field. 

This is a benefit to them, our company and the industry at large, as they will be the next generation of scientific talent helping drive breakthroughs in research and providing novel health care.

Read More

Insights from the Gene and Cell Therapy Meeting on the Mesa: 2016

Last month I took part in a workshop on gene and cell therapy manufacturing at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa. It was a pleasure to participate with very distinguished colleagues: Matthew Caple, Vice President of Site Operations at Brammer Bio; Mike Kelly, Director, Asset Leadership and Portfolio Management, Gene Therapy, Biogen; and Michael Roberts, Ph.D., Chief Scientific Officer, Synpromics.

The workshop was moderated by Jessica Carmen, Ph.D., Director of Business Development, Cellular Therapy Partnerships, MaxCyte and sponsored by MaxCyte and Brammer Bio. Dr. Carmen did a great job taking us on a journey through manufacturing from construct design through raw material manufacturing, viral vector manufacturing, and ultimately commercialization.

Read More

The Distinction Between Development and Manufacturing is Becoming Blurred

Last month, I participated in a panel discussion at the Rejuvenation Biotechnology 2016 Conference sponsored by the SENS Research Foundation at the Buck Institute for Research on Aging in Novato, California. The title of our panel was "As Paths To Clinic Are Expedited, The Distinction Between Development And Manufacturing Is Becoming Increasingly Blurred".

One of the panelists was Alan Moore, Vice President and Commercial Chief for Biologics and Advanced Therapies of Wuxi AppTec. Alan and I have known each other for some time and it was great to reconnect with him. His presentation covered the impressive work that Wuxi has done in autologous cell processing.

Read More